N. C. DEMİRCAN Et Al. , "Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy," JOURNAL OF BUON , vol.24, no.4, pp.1494-1500, 2019
DEMİRCAN, N. C. Et Al. 2019. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. JOURNAL OF BUON , vol.24, no.4 , 1494-1500.
DEMİRCAN, N. C., DANE, F., Ozturk, M. A., Babacan, N. A., Besiroglu, M., Kaya, S., ... Ercelep, O.(2019). Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. JOURNAL OF BUON , vol.24, no.4, 1494-1500.
DEMİRCAN, NAZIM Et Al. "Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy," JOURNAL OF BUON , vol.24, no.4, 1494-1500, 2019
DEMİRCAN, NAZIM C. Et Al. "Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy." JOURNAL OF BUON , vol.24, no.4, pp.1494-1500, 2019
DEMİRCAN, N. C. Et Al. (2019) . "Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy." JOURNAL OF BUON , vol.24, no.4, pp.1494-1500.
@article{article, author={NAZIM CAN DEMİRCAN Et Al. }, title={Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy}, journal={JOURNAL OF BUON}, year=2019, pages={1494-1500} }